FinnCap reissued their corporate rating on shares of Cello Health (LON:CLL) in a research report report published on Tuesday morning, ThisIsMoney.Co.Uk reports.
Shares of LON CLL opened at GBX 127 ($1.66) on Tuesday. The company has a current ratio of 1.28, a quick ratio of 1.23 and a debt-to-equity ratio of 4.70. The stock has a market capitalization of $134.73 million and a PE ratio of 20.82. The stock’s fifty day simple moving average is GBX 125.72 and its two-hundred day simple moving average is GBX 127.17. Cello Health has a 12-month low of GBX 95 ($1.24) and a 12-month high of GBX 140.07 ($1.83).
The business also recently announced a dividend, which will be paid on Friday, November 1st. Shareholders of record on Thursday, October 3rd will be given a dividend of GBX 1.15 ($0.02) per share. The ex-dividend date of this dividend is Thursday, October 3rd. This represents a yield of 0.91%. Cello Health’s dividend payout ratio (DPR) is presently 0.66%.
Cello Health Company Profile
Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients.
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Cello Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Health and related companies with MarketBeat.com's FREE daily email newsletter.